Quality of life (QOL) with sunitinib versus interferon-alfa (IFN-α) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): Final results.
暂无分享,去创建一个
R. Motzer | M. Michaelson | D. Cella | J. Cappelleri | A. Bushmakin | C. Charbonneau | S. Kim | J. Z. Li